Electron Kebebew, MD, Division of General Surgery, Stanford, CA
Allow more conservative procedures.
No need for experimental pharmaceuticals.
Radioguided surgery uses advanced probes to detect radiopharmaceuticals in tumors, enabling precise removal. At Radiantis Research, our Beta Probe 1 technology is redefining accuracy, making oncologic surgeries more effective and reliable.
At beginning of surgery, inject as low as 1 MBq/kG of β emitting tracer (e.g. 68Ga)
The tracer binds to tumor cells, that start emitting radiation
The surgeon uses the probe to idenfity in real time activity hotspots, thus suggesting the possible presence of tumor residual
Are you a clinician, surgeon, or nuclear medicine physician? Be among the first to access our breakthrough probe and revolutionize patient care.
Radiantis Research stands at the forefront of medical innovation, addressing
the critical landscape of cancer surgery, which plays a pivotal role in contemporary
healthcare. With cancer being a leading cause of morbidity
and mortality worldwide, the significance of advancements in surgical
techniques cannot be overstated.
In the ongoing battle against cancer, surgical interventions remain a cornerstone of
treatment.
Despite remarkable progress, there exists a pressing need for cutting-edge tools that can
empower surgeons, elevating the precision and efficacy of
oncological procedures. It's imperative to bridge the gap between the potential of modern
surgery and the challenges that persist in achieving consistently
high-quality outcomes across diverse medical centers.
Biomedical Engeneer, CEO.
Phyisicist, CTO.
Communications and Public Affairs.
Strategy and Business Development Advisor.
Medical consultant.
Medical Consultant.
RADIANTIS is an Innovative Startup, spinoff of the Italian National Institute for Nuclear Physics (INFN), licensee of a patent from INFN and Sapienza, Università di Roma.
